{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:27:26Z","timestamp":1781152046017,"version":"3.54.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Beijing Natural Science Foundation Grant","award":["L212039"],"award-info":[{"award-number":["L212039"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-D-004"],"award-info":[{"award-number":["2022-PUMCH-D-004"]}]},{"DOI":"10.13039\/501100009331","name":"Beijing Hospitals Authority Clinical Medicine Development of special funding support","doi-asserted-by":"crossref","award":["XMLX202138"],"award-info":[{"award-number":["XMLX202138"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-025-03204-x","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T23:49:15Z","timestamp":1737416955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The efficacy and safety of tyrosine kinase inhibitors in the treatment of advanced or metastatic chordoma: a single-arm meta-analysis"],"prefix":"10.1007","volume":"48","author":[{"given":"Hongfeng","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penghao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanru","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"issue":"3","key":"3204_CR1","first-page":"417","volume":"20","author":"JH Healey","year":"1989","unstructured":"Healey JH, Lane JM (1989) Chordoma: a critical review of diagnosis and treatment. Orthop Clin North Am 20(3):417\u2013426. https:\/\/pubmed.ncbi.nlm.nih.gov\/2662114","journal-title":"Orthop Clin North Am"},{"issue":"1","key":"3204_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/a:1008947301735","volume":"12","author":"ML McMaster","year":"2001","unstructured":"McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM (2001) Chordoma: incidence and survival patterns in the United States, 1973\u20131995. Cancer Causes Control 12(1):1\u201311. https:\/\/doi.org\/10.1023\/a:1008947301735","journal-title":"Cancer Causes Control"},{"issue":"11","key":"3204_CR3","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1634\/theoncologist.12-11-1344","volume":"12","author":"R Chugh","year":"2007","unstructured":"Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH (2007) Chordoma: the nonsarcoma primary bone tumor. Oncologist 12(11):1344\u20131350. https:\/\/doi.org\/10.1634\/theoncologist.12-11-1344","journal-title":"Oncologist"},{"issue":"3","key":"3204_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PAP.0000000000000293","volume":"28","author":"JH Choi","year":"2021","unstructured":"Choi JH, Ro JY (2021) The 2020 WHO classification of tumors of bone: an updated review. Adv Anat Pathol 28(3):119\u2013138. https:\/\/doi.org\/10.1097\/PAP.0000000000000293","journal-title":"Adv Anat Pathol"},{"issue":"5","key":"3204_CR5","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/neuros\/nyx081","volume":"81","author":"J Zhou","year":"2017","unstructured":"Zhou J, Sun J, Bai HX et al (2017) Prognostic factors in patients with spinal chordoma: an integrative analysis of 682 patients. Neurosurgery 81(5):812\u2013823. https:\/\/doi.org\/10.1093\/neuros\/nyx081","journal-title":"Neurosurgery"},{"issue":"2","key":"3204_CR6","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/S1470-2045(14)71190-8","volume":"16","author":"S Stacchiotti","year":"2015","unstructured":"Stacchiotti S, Sommer J (2015) Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol 16(2):e71\u2013e83. https:\/\/doi.org\/10.1016\/S1470-2045(14)71190-8","journal-title":"Lancet Oncol"},{"issue":"2","key":"3204_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/hed.20144","volume":"27","author":"WM Mendenhall","year":"2005","unstructured":"Mendenhall WM, Mendenhall CM, Lewis SB, Villaret DB, Mendenhall NP (2005) Skull base chordoma. Head Neck 27(2):159\u2013165. https:\/\/doi.org\/10.1002\/hed.20144","journal-title":"Head Neck"},{"issue":"1","key":"3204_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10143-011-0354-1","volume":"35","author":"F Gagliardi","year":"2012","unstructured":"Gagliardi F, Boari N, Riva P, Mortini P (2012) Current therapeutic options and novel molecular markers in skull base chordomas. Neurosurg Rev 35(1):1\u201313. https:\/\/doi.org\/10.1007\/s10143-011-0354-1","journal-title":"Neurosurg Rev"},{"issue":"5","key":"3204_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11864-021-00838-z","volume":"22","author":"JZ Passer","year":"2021","unstructured":"Passer JZ, Alvarez-Breckenridge C, Rhines L, DeMonte F, Tatsui C, Raza SM (2021) Surgical Management of Skull Base and Spine Chordomas. Curr Treat Options Oncol 22(5):40. https:\/\/doi.org\/10.1007\/s11864-021-00838-z","journal-title":"Curr Treat Options Oncol"},{"issue":"7","key":"3204_CR10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/00007632-198310000-00016","volume":"8","author":"HB Cotler","year":"1983","unstructured":"Cotler HB, Cotler JM, Cohn HE, Israel HI, Gartland JJ (1983) Intrathoracic chordoma presenting as a posterior superior mediastinal tumor. Spine 8(7):781\u2013786. https:\/\/pubmed.ncbi.nlm.nih.gov\/6665580","journal-title":"Spine"},{"issue":"10","key":"3204_CR11","first-page":"2211","volume":"87","author":"B Fuchs","year":"2005","unstructured":"Fuchs B, Dickey ID, Yaszemski MJ, Inwards CY, Sim FH (2005) Operative management of sacral chordoma. J bone Joint Surg Am Volume 87(10):2211\u20132216. https:\/\/pubmed.ncbi.nlm.nih.gov\/16203885","journal-title":"J bone Joint Surg Am Volume"},{"issue":"2","key":"3204_CR12","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.3171\/foc.2003.15.2.9","volume":"15","author":"DR Fourney","year":"2003","unstructured":"Fourney DR, Gokaslan ZL (2003) Current management of sacral chordoma. NeuroSurg Focus 15(2):E9. https:\/\/pubmed.ncbi.nlm.nih.gov\/15350040","journal-title":"NeuroSurg Focus"},{"issue":"2","key":"3204_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ijrobp.2016.10.006","volume":"97","author":"P Kabolizadeh","year":"2017","unstructured":"Kabolizadeh P, Chen Y-L, Liebsch N et al (2017) Updated Outcome and Analysis of Tumor Response in Mobile Spine and sacral chordoma treated with definitive high-dose Photon\/Proton Radiation Therapy. Int J Radiat Oncol Biol Phys 97(2):254\u2013262. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.10.006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"3204_CR14","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1007\/s10143-022-01880-7","volume":"45","author":"B Pahwa","year":"2022","unstructured":"Pahwa B, Medani K, Lu VM, Elarjani T (2022) Proton Beam therapy for skull base chordomas: a systematic review of tumor control rates and survival rates. Neurosurg Rev 45(6):3551\u20133563. https:\/\/doi.org\/10.1007\/s10143-022-01880-7","journal-title":"Neurosurg Rev"},{"issue":"4","key":"3204_CR15","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.ijrobp.2004.05.064","volume":"60","author":"H Igaki","year":"2004","unstructured":"Igaki H, Tokuuye K, Okumura T et al (2004) Clinical results of proton beam therapy for skull base chordoma. Int J Radiat Oncol Biol Phys 60(4):1120\u20131126. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.05.064","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3204_CR16","doi-asserted-by":"publisher","first-page":"109551","DOI":"10.1016\/j.radonc.2023.109551","volume":"183","author":"AM Chhabra","year":"2023","unstructured":"Chhabra AM, Rice SR, Holtzman A et al (2023) Clinical outcomes and toxicities of 100 patients treated with proton therapy for chordoma on the Proton collaborative group prospective registry. Radiother Oncol 183:109551. https:\/\/doi.org\/10.1016\/j.radonc.2023.109551","journal-title":"Radiother Oncol"},{"issue":"9","key":"3204_CR17","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1093\/neuonc\/noad068","volume":"25","author":"M Ioakeim-Ioannidou","year":"2023","unstructured":"Ioakeim-Ioannidou M, Niemierko A, Kim DW et al (2023) Surgery and proton radiation therapy for pediatric base of skull chordomas: long-term clinical outcomes for 204 patients. Neuro Oncol 25(9):1686\u20131697. https:\/\/doi.org\/10.1093\/neuonc\/noad068","journal-title":"Neuro Oncol"},{"issue":"1","key":"3204_CR18","doi-asserted-by":"publisher","first-page":"e2141927","DOI":"10.1001\/jamanetworkopen.2021.41927","volume":"5","author":"YU Yolcu","year":"2022","unstructured":"Yolcu YU, Zreik J, Wahood W et al (2022) Comparison of oncologic outcomes and Treatment-Related Toxicity of Carbon Ion Radiotherapy and En Bloc Resection for Sacral Chordoma. JAMA Netw Open 5(1):e2141927. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.41927","journal-title":"JAMA Netw Open"},{"key":"3204_CR19","doi-asserted-by":"crossref","unstructured":"York JE, Kaczaraj A, Abi-Said D et al (1999) Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery 44(1). https:\/\/pubmed.ncbi.nlm.nih.gov\/9894966","DOI":"10.1097\/00006123-199901000-00041"},{"issue":"15","key":"3204_CR20","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1200\/JCO.2005.02.170","volume":"23","author":"R Chugh","year":"2005","unstructured":"Chugh R, Dunn R, Zalupski MM et al (2005) Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol 23(15):3597\u20133604. https:\/\/pubmed.ncbi.nlm.nih.gov\/15908670","journal-title":"J Clin Oncol"},{"issue":"23","key":"3204_CR21","doi-asserted-by":"publisher","first-page":"6920","DOI":"10.1158\/1078-0432.CCR-06-1584","volume":"12","author":"E Tamborini","year":"2006","unstructured":"Tamborini E, Miselli F, Negri T et al (2006) Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res 12(23):6920\u20136928. https:\/\/pubmed.ncbi.nlm.nih.gov\/17145809","journal-title":"Clin Cancer Res"},{"key":"3204_CR22","doi-asserted-by":"crossref","unstructured":"Fasig JH, Dupont WD, LaFleur BJ, Olson SJ, Cates JMM (2008) Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma. Neuropathol Appl Neurobiol 34(1). https:\/\/pubmed.ncbi.nlm.nih.gov\/17973908","DOI":"10.1111\/j.1365-2990.2007.00873.x"},{"issue":"8","key":"3204_CR23","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1093\/neuonc\/noq003","volume":"12","author":"E Tamborini","year":"2010","unstructured":"Tamborini E, Virdis E, Negri T et al (2010) Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. Neurooncology 12(8):776\u2013789. https:\/\/doi.org\/10.1093\/neuonc\/noq003","journal-title":"Neurooncology"},{"issue":"1","key":"3204_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11060-019-03221-z","volume":"144","author":"Y Morimoto","year":"2019","unstructured":"Morimoto Y, Tamura R, Ohara K et al (2019) Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma. J Neurooncol 144(1):65\u201377. https:\/\/doi.org\/10.1007\/s11060-019-03221-z","journal-title":"J Neurooncol"},{"key":"3204_CR25","doi-asserted-by":"publisher","first-page":"1009193","DOI":"10.3389\/fonc.2022.1009193","volume":"12","author":"DM Freed","year":"2022","unstructured":"Freed DM, Sommer J, Punturi N (2022) Emerging target discovery and drug repurposing opportunities in chordoma. Front Oncol 12:1009193. https:\/\/doi.org\/10.3389\/fonc.2022.1009193","journal-title":"Front Oncol"},{"issue":"13","key":"3204_CR26","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","volume":"25","author":"H Choi","year":"2007","unstructured":"Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13):1753\u20131759. https:\/\/pubmed.ncbi.nlm.nih.gov\/17470865","journal-title":"J Clin Oncol"},{"key":"3204_CR27","doi-asserted-by":"publisher","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer. 1990 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"3204_CR28","doi-asserted-by":"publisher","unstructured":"Le Cesne A, Chevreau C, Perrin C et al (2023) Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study. ESMO Open 8(3). https:\/\/doi.org\/10.1016\/j.esmoop.2023.101569","DOI":"10.1016\/j.esmoop.2023.101569"},{"issue":"20","key":"3204_CR29","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1002\/cncr.31685","volume":"124","author":"S Stacchiotti","year":"2018","unstructured":"Stacchiotti S, Morosi C, Lo Vullo S et al (2018) Imatinib and Everolimus in patients with progressing Advanced Chordoma: a phase 2 clinical study. Cancer 124(20):4056\u20134063. https:\/\/doi.org\/10.1002\/cncr.31685","journal-title":"Cancer"},{"issue":"9","key":"3204_CR30","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1200\/JCO.2011.35.3656","volume":"30","author":"S Stacchiotti","year":"2012","unstructured":"Stacchiotti S, Longhi A, Ferraresi V et al (2012) Phase II study of Imatinib in Advanced Chordoma. J Clin Oncol 30(9):914\u2013920. https:\/\/doi.org\/10.1200\/JCO.2011.35.3656","journal-title":"J Clin Oncol"},{"issue":"7","key":"3204_CR31","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1093\/annonc\/mdt117","volume":"24","author":"S Stacchiotti","year":"2013","unstructured":"Stacchiotti S, Tamborini E, Lo Vullo S et al (2013) Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol 24(7):1931\u20131936. https:\/\/doi.org\/10.1093\/annonc\/mdt117","journal-title":"Ann Oncol"},{"issue":"9","key":"3204_CR32","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/S1470-2045(20)30466-6","volume":"21","author":"C Liu","year":"2020","unstructured":"Liu C, Jia Q, Wei H et al (2020) Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study. LANCET Oncol 21(9):1244\u20131252","journal-title":"LANCET Oncol"},{"issue":"1","key":"3204_CR33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/cncr.30379","volume":"123","author":"SM Schuetze","year":"2017","unstructured":"Schuetze SM, Bolejack V, Choy E et al (2017) Phase 2 study of Dasatinib in patients with alveolar soft part Sarcoma, Chondrosarcoma, Chordoma, Epithelioid Sarcoma, or Solitary Fibrous Tumor. Cancer 123(1):90\u201397. https:\/\/doi.org\/10.1002\/cncr.30379","journal-title":"Cancer"},{"issue":"10","key":"3204_CR34","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1093\/annonc\/mdv300","volume":"26","author":"E Bompas","year":"2015","unstructured":"Bompas E, Le Cesne A, Tresch-Bruneel E et al (2015) Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF\/GETO). Ann Oncol 26(10):2168\u20132173. https:\/\/doi.org\/10.1093\/annonc\/mdv300","journal-title":"Ann Oncol"},{"issue":"5","key":"3204_CR35","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.ijrobp.2018.07.2013","volume":"102","author":"GM Cote","year":"2018","unstructured":"Cote GM, Barysauskas CM, DeLaney TF et al (2018) A phase 1 study of Nilotinib Plus Radiation in High-Risk Chordoma. Int J Radiat Oncol Biol Phys 102(5):1496\u20131504. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.07.2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"3204_CR36","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1093\/annonc\/mdp210","volume":"20","author":"S Stacchiotti","year":"2009","unstructured":"Stacchiotti S, Marrari A, Tamborini E et al (2009) Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol 20(11):1886\u20131894. https:\/\/doi.org\/10.1093\/annonc\/mdp210","journal-title":"Ann Oncol"},{"issue":"17","key":"3204_CR37","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1016\/j.ejca.2015.07.038","volume":"51","author":"N Hindi","year":"2015","unstructured":"Hindi N, Casali PG, Morosi C et al (2015) Imatinib in advanced chordoma: a retrospective case series analysis. Eur J Cancer 51(17):2609\u20132614. https:\/\/doi.org\/10.1016\/j.ejca.2015.07.038","journal-title":"Eur J Cancer"},{"issue":"7","key":"3204_CR38","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1002\/cncr.34083","volume":"128","author":"GG Baldi","year":"2022","unstructured":"Baldi GG, Lo Vullo S, Grignani G et al (2022) Weekly cisplatin with or without imatinib in advanced chordoma: a retrospective case-series analysis from the Italian rare Cancers Network. Cancer 128(7):1439\u20131448. https:\/\/doi.org\/10.1002\/cncr.34083","journal-title":"Cancer"},{"key":"3204_CR39","doi-asserted-by":"publisher","unstructured":"Lebellec L, Chauffert B, Blay JY et al (2017) Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF\/GETO) and the Association des Neuro-Oncologues d\u2019Expression Fran\u00e7aise (ANOCEF). European journal of cancer. 1990 (79):119\u2013128. https:\/\/doi.org\/10.1016\/j.ejca.2017.03.037","DOI":"10.1016\/j.ejca.2017.03.037"},{"issue":"13","key":"3204_CR40","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","volume":"25","author":"H Choi","year":"2007","unstructured":"Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13):1753\u20131759. https:\/\/doi.org\/10.1200\/JCO.2006.07.3049","journal-title":"J Clin Oncol"},{"issue":"2","key":"3204_CR41","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1148\/radiol.2512081403","volume":"251","author":"S Stacchiotti","year":"2009","unstructured":"Stacchiotti S, Collini P, Messina A et al (2009) High-grade soft-tissue sarcomas: tumor response assessment\u2013pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 251(2):447\u2013456. https:\/\/doi.org\/10.1148\/radiol.2512081403","journal-title":"Radiology"},{"issue":"1","key":"3204_CR42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3892\/ol.2017.7323","volume":"15","author":"RDS Horta","year":"2018","unstructured":"Horta RDS, Giuliano A, Lavalle GE et al (2018) Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors. Oncol Lett 15(1):129\u2013136. https:\/\/doi.org\/10.3892\/ol.2017.7323","journal-title":"Oncol Lett"},{"issue":"9","key":"3204_CR43","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1002\/cncr.20618","volume":"101","author":"PG Casali","year":"2004","unstructured":"Casali PG, Messina A, Stacchiotti S et al (2004) Imatinib mesylate in chordoma. Cancer 101(9):2086\u20132097. https:\/\/pubmed.ncbi.nlm.nih.gov\/15372471","journal-title":"Cancer"},{"issue":"1","key":"3204_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11060-023-04477-2","volume":"165","author":"NJ Brown","year":"2023","unstructured":"Brown NJ, Gendreau J, Kuo CC et al (2023) Assessing survival outcomes and complication profiles following surgical excision and radiotherapy as interventions for skull base chordoma: a systematic review of operative margins and surgical approaches. J Neurooncol 165(1):41\u201351. https:\/\/doi.org\/10.1007\/s11060-023-04477-2","journal-title":"J Neurooncol"},{"issue":"6","key":"3204_CR45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","volume":"25","author":"T Darkow","year":"2007","unstructured":"Darkow T, Henk HJ, Thomas SK et al (2007) Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. PharmacoEconomics 25(6):481\u2013496. https:\/\/pubmed.ncbi.nlm.nih.gov\/17523753","journal-title":"PharmacoEconomics"},{"issue":"3","key":"3204_CR46","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12185-019-02596-z","volume":"109","author":"M Sakurai","year":"2019","unstructured":"Sakurai M, Kikuchi T, Karigane D et al (2019) Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia. Int J Hematol 109(3):292\u2013298. https:\/\/doi.org\/10.1007\/s12185-019-02596-z","journal-title":"Int J Hematol"},{"issue":"6","key":"3204_CR47","doi-asserted-by":"publisher","first-page":"188969","DOI":"10.1016\/j.bbcan.2023.188969","volume":"1878","author":"L Li","year":"2023","unstructured":"Li L, Zhang D, Wu Y, Wang J, Ma F (2023) Efficacy and safety of trastuzumab with or without a tyrosine kinase inhibitor for HER2-positive breast cancer: a systematic review and meta-analysis. Biochim Biophys Acta Rev Cancer 1878(6):188969. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188969","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3204_CR48","doi-asserted-by":"publisher","first-page":"102667","DOI":"10.1016\/j.ctrv.2023.102667","volume":"122","author":"H Bolek","year":"2024","unstructured":"Bolek H, Yeked\u00fcz E, \u00dcr\u00fcn Y (2024) Combination therapies in patients with favorable risk metastatic renal cell carcinoma: a systematic review and Meta-analysis. Cancer Treat Rev 122:102667. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102667","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"3204_CR49","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1186\/s12885-023-11548-0","volume":"23","author":"Y Song","year":"2023","unstructured":"Song Y, Lin S, Chen J, Dang J (2023) First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis. BMC Cancer 23(1):1043. https:\/\/doi.org\/10.1186\/s12885-023-11548-0","journal-title":"BMC Cancer"},{"key":"3204_CR50","doi-asserted-by":"publisher","first-page":"103393","DOI":"10.1016\/j.critrevonc.2021.103393","volume":"163","author":"Y Chen","year":"2021","unstructured":"Chen Y, Wen S, Wu Y, Shi L, Xu X, Shen B (2021) Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: a systematic review and meta-analysis. Crit Rev Oncol\/Hematol 163:103393. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103393","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"9","key":"3204_CR51","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/s41419-018-0900-7","volume":"9","author":"W Li","year":"2018","unstructured":"Li W, Ji M, Lu F et al (2018) Novel AF1q\/MLLT11 favorably affects imatinib resistance and cell survival in chronic myeloid leukemia. Cell Death Dis 9(9):855. https:\/\/doi.org\/10.1038\/s41419-018-0900-7","journal-title":"Cell Death Dis"},{"issue":"10","key":"3204_CR52","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1097\/CAD.0b013e328330c7f0","volume":"20","author":"N Singhal","year":"2009","unstructured":"Singhal N, Kotasek D, Parnis FX (2009) Response to erlotinib in a patient with treatment refractory chordoma. Anticancer Drugs 20(10):953\u2013955. https:\/\/doi.org\/10.1097\/CAD.0b013e328330c7f0","journal-title":"Anticancer Drugs"},{"issue":"1","key":"3204_CR53","doi-asserted-by":"publisher","first-page":"2077898","DOI":"10.1080\/2162402X.2022.2077898","volume":"11","author":"A Petrazzuolo","year":"2022","unstructured":"Petrazzuolo A, Maiuri MC, Zitvogel L, Kroemer G, Kepp O (2022) Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. Oncoimmunology 11(1):2077898. https:\/\/doi.org\/10.1080\/2162402X.2022.2077898","journal-title":"Oncoimmunology"},{"issue":"3","key":"3204_CR54","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2009.06.021","volume":"75","author":"HW Chung","year":"2009","unstructured":"Chung HW, Wen J, Lim J-B, Bang S, Park SW, Song SY (2009) Radiosensitization effect of STI-571 on pancreatic cancer cells in vitro. Int J Radiat Oncol Biol Phys 75(3):862\u2013869. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.06.021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"3204_CR55","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/bloodadvances.2021004607","volume":"6","author":"I Sugiura","year":"2022","unstructured":"Sugiura I, Doki N, Hata T et al (2022) Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Adv 6(2):624\u2013636. https:\/\/doi.org\/10.1182\/bloodadvances.2021004607","journal-title":"Blood Adv"},{"issue":"1","key":"3204_CR56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.20892\/j.issn.2095-3941.2017.0118","volume":"15","author":"Y Chen","year":"2018","unstructured":"Chen Y, Wang Y, Zhao L et al (2018) EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation. Cancer Biol Med 15(1):39\u201351. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2017.0118","journal-title":"Cancer Biol Med"},{"issue":"15suppl","key":"3204_CR57","doi-asserted-by":"publisher","first-page":"11520","DOI":"10.1200\/JCO.2021.39.15_suppl.11520","volume":"39","author":"J-Y Blay","year":"2021","unstructured":"Blay J-Y, Penel N, Ray-Coquard IL et al (2021) High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: the French AcS\u00e9 pembrolizumab study from Unicancer. J Clin Oncol 39(15suppl):11520\u201311520. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.11520","journal-title":"J Clin Oncol"},{"key":"3204_CR58","doi-asserted-by":"publisher","first-page":"100194","DOI":"10.1016\/j.cpccr.2022.100194","volume":"8","author":"G-oE Ibodeng","year":"2022","unstructured":"Ibodeng G-oE, Alkharabsheh O, Thanikachalam K (2022) A case of refractory chordoma of the clivus with a review of therapeutic targets. Curr Probl Cancer: Case Rep 8:100194. https:\/\/doi.org\/10.1016\/j.cpccr.2022.100194","journal-title":"Curr Probl Cancer: Case Rep"},{"issue":"8","key":"3204_CR59","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/CJI.0000000000000431","volume":"45","author":"AJ Bishop","year":"2022","unstructured":"Bishop AJ, Amini B, Lin H et al (2022) Immune checkpoint inhibitors have clinical activity in patients with recurrent Chordoma. J Immunother 45(8):374\u2013378. https:\/\/doi.org\/10.1097\/CJI.0000000000000431","journal-title":"J Immunother"},{"issue":"5","key":"3204_CR60","doi-asserted-by":"publisher","first-page":"e847","DOI":"10.1002\/onco.13720","volume":"26","author":"PJ DeMaria","year":"2021","unstructured":"DeMaria PJ, Bilusic M, Park DM et al (2021) Randomized, Double-Blind, placebo-controlled phase II study of yeast-brachyury vaccine (GI-6301) in combination with standard-of-care Radiotherapy in locally Advanced, Unresectable Chordoma. Oncologist 26(5):e847\u2013e858. https:\/\/doi.org\/10.1002\/onco.13720","journal-title":"Oncologist"},{"key":"3204_CR61","doi-asserted-by":"publisher","unstructured":"DeMaria PJ, Lee-Wisdom K, Donahue RN et al (2021) Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. J Immunother Cancer 9(9). https:\/\/doi.org\/10.1136\/jitc-2021-003238","DOI":"10.1136\/jitc-2021-003238"},{"issue":"11","key":"3204_CR62","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/2326-6066.CIR-15-0119","volume":"3","author":"CR Heery","year":"2015","unstructured":"Heery CR, Singh BH, Rauckhorst M et al (2015) Phase I trial of a yeast-based therapeutic Cancer vaccine (GI-6301) targeting the transcription factor brachyury. Cancer Immunol Res 3(11):1248\u20131256. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0119","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"3204_CR63","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M et al (2021) Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 384(9):829\u2013841. https:\/\/doi.org\/10.1056\/NEJMoa2026982","journal-title":"N Engl J Med"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-025-03204-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-025-03204-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-025-03204-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T04:13:17Z","timestamp":1772079197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-025-03204-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3204"],"URL":"https:\/\/doi.org\/10.1007\/s10143-025-03204-x","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"27 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal participants that required informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}